Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.61 |
| ▸ | OSBP | P22059 | 1/20 | 0.61 |
| ▸ | RORC | P51449 | 1/20 | 0.61 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.61 |
| ▸ | POLA1 | P09884 | 1/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 13/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 11/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4430724 | 0.94 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL6816995 | 0.92 | USP2 (0.57) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL8159169 | 0.92 | OSBP (0.65) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL12274582 | 0.90 | USP2 (0.61) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL27963051 | 0.87 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL27963054 | 0.87 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2638134 | 0.87 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL27975861 | 0.87 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL6060845 | 0.87 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL565022 | 0.87 | USP2 (0.58) | USP2CYP46A1LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118234486-A | Uric acid liposome | 巴塞罗纳医院门诊部 | 2024-06-21 | — | — | CN | claimed |
| CN-115957382-A | Medical instrument for interventional therapy | 凯诺威医疗科技(武汉)有限公司 | 2023-04-14 | — | — | CN | claimed |
| US-10098987-B2 | Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs | M.A. Med Alliance SA (CH) | 2018-10-16 | — | — | US | claimed |
| US-9895313-B2 | Combination liposomal pharmaceutical formulations | CUREPORT INC (US) | 2018-02-20 | — | — | US | claimed |
| EP-3265063-A1 | DUAL LOADED LIPOSOMAL PHARMACEUTICAL FORMULATIONS | Cureport, Inc. (US) | 2018-01-10 | — | — | EP | claimed |
| EP-3265059-A1 | COMBINATION LIPOSOMAL PHARMACEUTICAL FORMULATIONS | Cureport Inc. (US) | 2018-01-10 | — | — | EP | claimed |
| US-20160256389-A1 | COMBINATION LIPOSOMAL PHARMACEUTICAL FORMULATIONS | CUREPORT INC (US) | 2016-09-08 | — | — | US | claimed |
| EP-1289642-B2 | NANOCAPSULES HAVING A POLYELECTROLYTE ENVELOPE | CAPSULUTION PHARMA AG (DE) | 2012-10-10 | — | — | EP | claimed |
| US-7763275-B2 | Template particles are supplied in aqueous medium, electrically charged with polyelectrolyte, recharged without separation or washing steps using second polyelectrolyte having complementary charge with respect to first | NOVOSOM AG (DE) | 2010-07-27 | — | — | US | claimed |
| US-20090304801-A1 | AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE | ELAN PHARMA INTERNATIONAL LIMITED | 2009-12-10 | — | — | US | claimed |
| EP-1663158-A2 | SPECIFIC DELIVERY OF DRUGS TO THE BRAIN | BAXTER INTERNATIONAL INC. (US) | 2006-06-07 | — | — | EP | claimed |
| EP-1628641-A2 | SOLID PARTICLES COMPRISING AN ANTICONVULSANT OR AN IMMUNOSUPPRESSIVE COATED WITH ONE OR MORE SURFACE MODIFIERS | BAXTER INTERNATIONAL INC. (US) | 2006-03-01 | — | — | EP | claimed |
| EP-1289642-B1 | NANOCAPSULES HAVING A POLYELECTROLYTE ENVELOPE | NOVOSOM AG (DE) | 2006-02-08 | — | — | EP | claimed |
| US-20050244503-A1 | Small-particle pharmaceutical formulations of antiseizure and antidementia agents and immunosuppressive agents | BAXTER HEALTHCARE S.A. (CH) | 2005-11-03 | — | — | US | claimed |
| US-20050048002-A1 | Dispersion; controlling particle size; preabsorption of drug by cells before administering; transferring to brain | BAXTER INTERNATIONAL INC. | 2005-03-03 | — | — | US | claimed |
| WO-2004112747-A2 | SPECIFIC DELIVERY OF DRUGS TO THE BRAIN | BAXTER INTERNATIONAL INC. (US) | 2004-12-29 | — | — | WO | claimed |
| WO-2004103348-A2 | SOLID PARTICLES COMPRISING AN ANTICONVULSANT OR AN IMMUNOSUPPRESSIVE COATED WITH ONE OR MORE SURFACE MODIFIERS | BAXTER INTERNATIONAL INC. (US) | 2004-12-02 | — | — | WO | claimed |
| US-20030157181-A1 | Nanocapsules having a polyelectrolyte envelope | CAPSULUTION PHARMA AG (DE) | 2003-08-21 | — | — | US | claimed |
| EP-1289642-A1 | NANOCAPSULES HAVING A POLYELECTROLYTE ENVELOPE | Novosom AG (DE) | 2003-03-12 | — | — | EP | claimed |
| WO-2001064330-A1 | NANOCAPSULES HAVING A POLYELECTROLYTE ENVELOPE | NOVOSOM AG (DE) | 2001-09-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304801-A1 | AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE | GABRA1, GABRA4, GABRA6 | USP2 1555/4885CYP46A1 1278/4885LMNA 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.